Top

Published in:

01-12-2010 | Advances and Challenges in PKU

Nutritional issues in treating phenylketonuria

Authors: François Feillet, Carlo Agostoni

Published in: Journal of Inherited Metabolic Disease | Issue 6/2010

Abstract

A phenylalanine (Phe)-restricted diet is the mainstay of phenylketonuria (PKU) treatment, and, in recent years, the nutritional management of PKU has become more complex in order to optimize patients’ growth, development and diet compliance. Dietary restriction of Phe creates a diet similar to a vegan diet, and many of the nutritional concerns and questions applicable to vegans who wish to avoid animal products are also relevant to patients with PKU. Owing to their nutritional characteristics, breast milk and breastfeeding should be given greater consideration as a useful food in patients with PKU and in those with other inborn errors of metabolism. Further key issues for consideration include the quality of the available amino acid substitutes, the neurotrophic and neuroprotective effects of added long-chain polyunsaturated fatty acids (e.g. docosahexaenoic acid), micronutrient deficiencies, bone disease and antioxidant status. Long-term dietary guidance and monitoring of the nutritional status of patients with PKU should be part of a follow-up programme that continues for life.

Agostoni C, Verduci E, Fiori L, Riva E, Giovannini M (2000a) Breastfeeding rates among hyperphenylalaninemic infants. Acta Paediatr 89:366–367CrossRefPubMed

Agostoni C, Massetto N, Biasucci G et al (2000b) Effects of long-chain polyunsaturated fatty acid supplementation on fatty acid status and visual function in treated children with hyperphenylalaninemia. J Pediatr 137:504–509CrossRefPubMed

Agostoni C, Verduci E, Massetto N, Radaelli G, Riva E, Giovannini M (2003a) Plasma long-chain polyunsaturated fatty acids and neurodevelopment through the first 12 months of life in phenylketonuria. Dev Med Child Neurol 45:257–261CrossRefPubMed

Agostoni C, Verduci E, Massetto N et al (2003b) Long term effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Arch Dis Child 88:582–583CrossRefPubMed

Agostoni C, Harvie A, McCulloch DL et al (2006) A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. Dev Med Child Neurol 48:207–212CrossRefPubMed

Agostoni C, Decsi T, Fewtrell M et al (2008) Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 46:99–110CrossRefPubMed

Al-Qadreh A, Schulpis KH, Athanasopoulou H, Mengreli C, Skarpalezou A, Voskaki I (1998) Bone mineral status in children with phenylketonuria under treatment. Acta Paediatr 87:1162–1166CrossRefPubMed

Ambroszkiewicz J, Gajewska J, Chelchowska M et al (2008) Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria (in Polish). Pol Merkuriusz Lek 25:57–60

American Dietetic Association, Dietitians of Canada (2003) Position of the American Dietetic Association and Dietitians of Canada: vegetarian diets. Can J Diet Pract Res 64:62–81CrossRef

Anderson JW, Johnstone BM, Remley DT (1999) Breast-feeding and cognitive development: a meta-analysis. Am J Clin Nutr 70:525–535PubMed

Artuch R, Colomé C, Sierra C et al (2004) A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 37:198–203CrossRefPubMed

Barat P, Barthe N, Redonnet-Vernhet I, Parrot F (2002) The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur J Pediatr 161:687–688CrossRefPubMed

Bazan NG (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 10:136–141CrossRefPubMed

Beblo S, Reinhardt H, Muntau AC, Mueller-Felber W, Roscher AA, Koletzko B (2001) Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 57:1488–1491PubMed

Beblo S, Reinhardt H, Demmelmair H, Muntau AC, Koletzko B (2007) Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 150:479–484CrossRefPubMed

Cleary MA, Feillet F, White FJ et al (2006) Randomised controlled trial of essential fatty acid supplementation in phenylketonuria. Eur J Clin Nutr 60:915–920CrossRefPubMed

Colomé C, Sierra C, Vilaseca MA (2000) Congenital errors of metabolism: cause of oxidative stress? Med Clin (Barc) 115:111–117

Colomé C, Artuch R, Vilaseca MA et al (2002) Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin Biochem 35:81–84CrossRefPubMed

Dagnelie PC, van Staveren WA (1994) Macrobiotic nutrition and child health: results of a population-based, mixed-longitudinal cohort study in The Netherlands. Am J Clin Nutr 59(5 Suppl):1187S–1196SPubMed

Fusco D, Colloca G, Lo Monaco MR, Cesari M (2007) Effects of antioxidant supplementation on the aging process. Clin Interv Aging 2:377–387PubMed

Galli C, Agostoni C, Mosconi C, Riva E, Salari PC, Giovannini M (1991) Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. J Pediatr 119:562–567CrossRefPubMed

Gutteridge JM, Halliwell B (2000) Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 899:136–147CrossRefPubMed

Huner G, Baykal T, Demir F, Demirkol M (2005) Breastfeeding experience in inborn errors of metabolism other than phenylketonuria. J Inherit Metab Dis 28:457–465CrossRefPubMed

Hvas AM, Nexo E, Nielsen JB (2006) Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU). J Inherit Metab Dis 29:47–53CrossRefPubMed

Karlsson KM, Karlsson C, Ahlborg HG, Valdimarsson O, Ljunghall S, Obrant KJ (2003) Bone turnover responses to changed physical activity. Calcif Tissue Int 72:675–680CrossRefPubMed

Koletzko B, Lien E, Agostoni C et al (2008) The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 36:5–14CrossRefPubMed

MacDonald A, Ferguson C, Rylance G et al (2003) Are tablets a practical source of protein substitute in phenylketonuria? Arch Dis Child 88:327–329CrossRefPubMed

MacDonald A, Lilburn M, Cochrane B et al (2004) A new, low-volume protein substitute for teenagers and adults with phenylketonuria. J Inherit Metab Dis 27:127–135CrossRefPubMed

MacDonald A, Depondt E, Evans S et al (2006a) Breastfeeding in IMD. J Inherit Metab Dis 29:299–303CrossRefPubMed

MacDonald A, Lilburn M, Davies P et al (2006b) ‘Ready to drink’ protein substitute is easier is for people with phenylketonuria. J Inherit Metab Dis 29:526–531CrossRefPubMed

Mangels AR, Messina V (2001) Considerations in planning vegan diets: infants. J Am Diet Assoc 101:670–677CrossRefPubMed

McCarty MF (2001) Does a vegan diet reduce risk for Parkinson’s disease? Med Hypotheses 57:318–323CrossRefPubMed

Messina V, Mangels AR (2001) Considerations in planning vegan diets: children. J Am Diet Assoc 101:661–669CrossRefPubMed

Millet P, Vilaseca MA, Valls C et al (2005) Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria? Clin Biochem 38:1127–1132CrossRefPubMed

Modan-Moses D, Vered I, Schwartz G et al (2007) Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 30:202–208CrossRefPubMed

Moseley K, Koch R, Moser AB (2002) Lipid status and long-chain polyunsaturated fatty acid concentrations in adults and adolescents with phenylketonuria on phenylalanine-restricted diet. J Inherit Metab Dis 25:56–64CrossRefPubMed

Praticò D (2008) Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147:70–78CrossRefPubMed

Porta F, Roato I, Mussa A et al (2008) Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria. J Inherit Metab Dis, epub ahead of print

Rake JP, Visser G, Huismans D et al (2003) Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit Metab Dis 26:371–384CrossRefPubMed

Riva E, Agostoni C, Biasucci G et al (1996) Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children. Acta Paediatr 85:56–58CrossRefPubMed

Rohr FJ, Munier AW, Levy HL (2001) Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria. J Inherit Metab Dis 24:623–630CrossRefPubMed

Rutherford P, Poustie VJ (2005) Protein substitute for children and adults with phenylketonuria. Cochrane Database Syst Rev 4:CD004731PubMed

Schönau E, Schwahn B, Rauch F (2002) The muscle-bone relationship: methods and management—perspectives in glycogen storage disease. Eur J Pediatr 161:S50–S52PubMed

Schulpis KH, Tsakiris S, Karikas GA, Moukas M, Behrakis P (2003) Effect of diet on plasma total antioxidant status in phenylketonuric patients. Eur J Clin Nutr 57:383–387CrossRefPubMed

Schulpis KH, Karakonstantakis T, Bartzeliotou A, Karikas GA, Papassotiriou I (2004) The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet. Clin Nutr 23:401–407CrossRefPubMed

Schulpis KH, Tsakiris S, Traeger-Synodinos J, Papassotiriou I (2005) Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria. Clin Biochem 38:239–242CrossRefPubMed

Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schönau E (1998) Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr 87:61–63CrossRefPubMed

Schwahn B, Rauch F, Wendel U, Schönau E (2002) Low bone mass in glycogen storage disease type 1 is associated with reduced muscle force and poor metabolic control. J Pediatr 141:350–356CrossRefPubMed

Sirtori LR, Dutra-Filho CS, Fitarelli D et al (2005) Oxidative stress in patients with phenylketonuria. Biochim Biophys Acta 1740:68–73PubMed

Sitta A, Barschak AG, Deon M et al (2006) Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis 21:287–296CrossRefPubMed

van Bakel MM, Printzen G, Wermuth B, Wiesmann UN (2000) Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am J Clin Nutr 72:976–981PubMed

van Rijn M, Bekhof J, Dijkstra T, Smit PG, Moddermam P, van Spronsen FJ (2003) A different approach to breast-feeding of the infant with phenylketonuria. Eur J Pediatr 162:323–326PubMed

Verduci E, Agostoni C, Biondi ML, Radaelli G, Giovannini M, Riva E (2004) Apolipoprotein B gene polymorphism and plasma lipid levels in phenylketonuric children. Prostaglandins Leukot Essent Fatty Acids 71:117–120CrossRefPubMed

Wajner M, Latini A, Wyse AT, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427–448CrossRefPubMed

Title: Nutritional issues in treating phenylketonuria
Authors: François Feillet
Carlo Agostoni
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 6/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-010-9043-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle

Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy

Erratum to: Phenylalanine loading in pediatric patients with dopa-responsive dystonia: revised test protocol and pediatric cutoff values

Therapeutic liver repopulation for phenylketonuria

Mutations in the promoter region of the aldolase B gene that cause hereditary fructose intolerance

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials